Overview

Pembrolizumab + Imprime PGG for Metastatic Non-small Cell Lung Cancer After Progression on First-Line Therapy: Big Ten Cancer Research Consortium BTCRC-LUN15-017

Status:
Active, not recruiting

Trial end date:
2021-09-01

Target enrollment:

Participant gender:

Summary

This is an open label, multi-institutional, single arm study with a dose escalation phase Ib cohort, followed by a phase II cohort of pembrolizumab and Imprime PGG. No randomization or blinding is involved.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Lawrence Feldman
Lawrence Feldman, MD

Collaborators:

Biothera
HiberCell, Inc.
Merck Sharp & Dohme Corp.

Treatments:

Pembrolizumab